| Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy BM Brenner, ME Cooper, D De Zeeuw, WF Keane, WE Mitch, HH Parving, ... New England journal of medicine 345 (12), 861-869, 2001 | 9654 | 2001 |
| Heart disease and stroke statistics 2005 update American Heart Association http://www. americanheart. org/statistics/, 2005 | 8554* | 2005 |
| Canagliflozin and cardiovascular and renal events in type 2 diabetes B Neal, V Perkovic, KW Mahaffey, D De Zeeuw, G Fulcher, N Erondu, ... New England Journal of Medicine 377 (7), 644-657, 2017 | 7935 | 2017 |
| Canagliflozin and renal outcomes in type 2 diabetes and nephropathy V Perkovic, MJ Jardine, B Neal, S Bompoint, HJL Heerspink, ... New England journal of medicine 380 (24), 2295-2306, 2019 | 5173 | 2019 |
| The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo … C Baigent, MJ Landray, C Reith, J Emberson, DC Wheeler, C Tomson, ... The Lancet 377 (9784), 2181-2192, 2011 | 2961 | 2011 |
| A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease MA Pfeffer, EA Burdmann, CY Chen, ME Cooper, D De Zeeuw, ... New England Journal of Medicine 361 (21), 2019-2032, 2009 | 2449 | 2009 |
| Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population HL Hillege, V Fidler, GFH Diercks, WH van Gilst, D de Zeeuw, ... Circulation 106 (14), 1777-1782, 2002 | 1799 | 2002 |
| Cardiorenal end points in a trial of aliskiren for type 2 diabetes HH Parving, BM Brenner, JJV McMurray, D De Zeeuw, SM Haffner, ... New England Journal of Medicine 367 (23), 2204-2213, 2012 | 1642 | 2012 |
| Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis TH Jafar, PC Stark, CH Schmid, M Landa, G Maschio, PE De Jong, ... Annals of internal medicine 139 (4), 244-252, 2003 | 1446 | 2003 |
| Renal function, neurohormonal activation, and survival in patients with chronic heart failure HL Hillege, ARJ Girbes, PJ De Kam, F Boomsma, D De Zeeuw, ... Circulation 102 (2), 203-210, 2000 | 1426 | 2000 |
| Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease: a meta-analysis of patient-level data TH Jafar, CH Schmid, M Landa, I Giatras, R Toto, G Remuzzi, G Maschio, ... Annals of internal medicine 135 (2), 73-87, 2001 | 1352 | 2001 |
| Factors influencing serum cystatin C levels other than renal function and the impact on renal function measurement EL Knight, JC Verhave, D Spiegelman, HL Hillege, D De Zeeuw, ... Kidney international 65 (4), 1416-1421, 2004 | 1342 | 2004 |
| Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL D De Zeeuw, G Remuzzi, HH Parving, WF Keane, Z Zhang, S Shahinfar, ... Kidney international 65 (6), 2309-2320, 2004 | 1235 | 2004 |
| Renal function as a predictor of outcome in a broad spectrum of patients with heart failure HL Hillege, D Nitsch, MA Pfeffer, K Swedberg, JJV McMurray, S Yusuf, ... Circulation 113 (5), 671-678, 2006 | 1192 | 2006 |
| Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease D De Zeeuw, T Akizawa, P Audhya, GL Bakris, M Chin, H Christ-Schmidt, ... New England Journal of Medicine 369 (26), 2492-2503, 2013 | 1046 | 2013 |
| Albuminuria, a therapeutic target for cardiovascular protection in type 2 diabetic patients with nephropathy D De Zeeuw, G Remuzzi, HH Parving, WF Keane, Z Zhang, S Shahinfar, ... Circulation 110 (8), 921-927, 2004 | 1030 | 2004 |
| Microalbuminuria is common, also in a nondiabetic, nonhypertensive population, and an independent indicator of cardiovascular risk factors and cardiovascular morbidity HL Hillege, WMT Janssen, AAA Bak, GFH Diercks, DE Grobbee, H Crijns, ... Journal of internal medicine 249 (6), 519-526, 2001 | 914 | 2001 |
| Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial D De Zeeuw, R Agarwal, M Amdahl, P Audhya, D Coyne, T Garimella, ... The Lancet 376 (9752), 1543-1551, 2010 | 903 | 2010 |
| Dapagliflozin a glucose‐regulating drug with diuretic properties in subjects with type 2 diabetes HJ Lambers Heerspink, D De Zeeuw, L Wie, B Leslie, J List Diabetes, Obesity and Metabolism 15 (9), 853-862, 2013 | 892 | 2013 |
| Lower estimated glomerular filtration rate and higher albuminuria are associated with mortality and end-stage renal disease. A collaborative meta-analysis of kidney disease … BC Astor, K Matsushita, RT Gansevoort, M Van Der Velde, M Woodward, ... Kidney international 79 (12), 1331-1340, 2011 | 807 | 2011 |
